Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sarcoma,Soft Tissue: early-phase trial registry
3 of 13 indexed Sarcoma,Soft Tissue trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 3 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Sarcoma,Soft Tissue: 13 US clinical trials tracked, 3 recruiting.
Sarcoma,Soft Tissue is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition sarcomasoft-tissue
OPEN 3 | RECR 23% | LATE 2 | EARLY 9 | RANK #1315 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Endometrial Serous Adenocarcinoma (23% recruiting · 13 trials)
Sarcoma,Soft Tissue lists 3 open slots (23% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sarcoma,Soft Tissue on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sarcoma,Soft Tissue is recruiting below its size-band peers.
3 of 13 indexed trials (23.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Sarcoma,Soft Tissue research.
Memorial Sloan Kettering Cancer Center accounts for 4 of 13 trials (30.8%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Sarcoma,Soft Tissue trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.
-
Sarcoma,Soft Tissue research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx
NCT04673942
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT04577014
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Wake Forest University Health Sciences
NCT07291297
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Intensity Therapeutics
NCT06263231
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT05886634
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
University of California, Irvine
NCT05488366
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Memorial Sloan Kettering Cancer Center
NCT05515575
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
NCT05813327
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
John Rieth
NCT06660810
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT00142571
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
NCT00490451
Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma
The Cleveland Clinic
NCT02897128
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Medical College of Wisconsin
NCT01949506
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Sarcoma,Soft Tissue records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sarcoma,Soft Tissue trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sarcoma,Soft Tissue page
13 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Sarcoma,Soft Tissue trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Sarcoma,Soft Tissue trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoma,Soft Tissue condition card totals 13 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.